Abstract
Cell cycle progression and cell division are driven by the sequential activation of a group of serine-threonine kinases called cyclin-dependent kinases (Cdks). Multiple Cdks control the cell cycle in mammals and have been long considered essential for normal proliferation, development and homeostasis. The importance of the Cdk-cyclin complexes in cell proliferation is underscored by the fact that deregulation of the Cdk activity is found in virtually the whole spectrum of human tumors. Advances in the cell cycle proteins in the last 25 years, since the discovery of cyclins, have been discussed and have shed even more light on this essential life sustaining process. Recent information from different models for the various cyclins and Cdks have made some of the generally accepted concepts of cell cycle regulation to be revised and new and exciting questions to be investigated. There is also increasing evidence that suggests that Cdks such as Cdc2 are also commonly targeted by viral proteins, which modulate host cell cycle machinery to benefit viral survival or replication. This review, describes some of the most recent and important US patents related to cell cycle regulation and those on viral proteins involved in cell cycle modulation particularly the G2/M phase transition and cancer therapy.
Keywords: Cell cycle regulation, cyclin dependent kinases, cyclins, cell cycle modulation, viral proteins, G2/M phase
Recent Patents on Biotechnology
Title: Recent Patents on Cell Cycle Regulatory Proteins
Volume: 3 Issue: 1
Author(s): Julius L. C. Chulu and Hung J. Liu
Affiliation:
Keywords: Cell cycle regulation, cyclin dependent kinases, cyclins, cell cycle modulation, viral proteins, G2/M phase
Abstract: Cell cycle progression and cell division are driven by the sequential activation of a group of serine-threonine kinases called cyclin-dependent kinases (Cdks). Multiple Cdks control the cell cycle in mammals and have been long considered essential for normal proliferation, development and homeostasis. The importance of the Cdk-cyclin complexes in cell proliferation is underscored by the fact that deregulation of the Cdk activity is found in virtually the whole spectrum of human tumors. Advances in the cell cycle proteins in the last 25 years, since the discovery of cyclins, have been discussed and have shed even more light on this essential life sustaining process. Recent information from different models for the various cyclins and Cdks have made some of the generally accepted concepts of cell cycle regulation to be revised and new and exciting questions to be investigated. There is also increasing evidence that suggests that Cdks such as Cdc2 are also commonly targeted by viral proteins, which modulate host cell cycle machinery to benefit viral survival or replication. This review, describes some of the most recent and important US patents related to cell cycle regulation and those on viral proteins involved in cell cycle modulation particularly the G2/M phase transition and cancer therapy.
Export Options
About this article
Cite this article as:
Chulu L. C. Julius and Liu J. Hung, Recent Patents on Cell Cycle Regulatory Proteins, Recent Patents on Biotechnology 2009; 3 (1) . https://dx.doi.org/10.2174/187220809787172614
DOI https://dx.doi.org/10.2174/187220809787172614 |
Print ISSN 1872-2083 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4012 |
Call for Papers in Thematic Issues
Advancements in Plant Genetics and Genomics
This thematic issue will highlight cutting-edge innovations and recent patents across the breadth of plant genetics and genomics. Key topics will include advanced breeding techniques, omics-based approaches, gene editing, trait discovery, and translational applications for crop improvement. Renowned researchers from leading institutions worldwide will provide state-of-the-art insights and future perspectives ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Epidemiology, Clinical Presentation and Treatment of Uveal Melanoma
Clinical Cancer Drugs Bisphosphonates: Molecular Mechanisms of Action and Effects on Bone Cells, Monocytes and Macrophages
Current Pharmaceutical Design The Medical Potential of Antimicrobial Peptides from Insects
Current Topics in Medicinal Chemistry Liposomal Formulation of Monovalent Cholesteryl Cytofectins with Acyclic Head Groups and Gene Delivery: A Systematic Review
Current Pharmaceutical Biotechnology Circulating Biomarkers for Tumor Angiogenesis: Where Are We?
Current Medicinal Chemistry Namitecan: a Hydrophilic Camptothecin with a Promising Preclinical Profile
Current Medicinal Chemistry Prognostic and Therapeutic Implications of MicroRNA in Malignant Pleural Mesothelioma
MicroRNA Patent Selections
Recent Patents on Biomarkers Peeking into the Black Box: How Cytokine Antibody Arrays Shed Light on Molecular Mechanisms of Breast Cancer Development and its Treatment
Current Proteomics Editorial: (Thematic Issue: Occupational Exposure: An Undermined Risk Factor of Lung Diseases in the Informal Sectors of Developing Economy)
Current Respiratory Medicine Reviews Design Strategies, Structures and Molecular Interactions of Small Molecule Src Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Structural and Bioactive Properties of 3-O-Methylfunicone
Mini-Reviews in Medicinal Chemistry Too Much of a Good Thing: Suicide Prevention Promotes Chemoresistance in Ovarian Carcinoma
Current Cancer Drug Targets Role of α7-Nicotinic Acetylcholine Receptor in Normal and Cancer Stem Cells
Current Drug Targets Novel Agents in the Management of Lung Cancer
Current Medicinal Chemistry New Poly(3-hydroxybutyrate) Microparticles with Paclitaxel Sustained Release for Intraperitoneal Administration
Anti-Cancer Agents in Medicinal Chemistry miR-149 as a Potential Molecular Target for Cancer
Current Medicinal Chemistry Sorafenib (BAY 43-9006) in Hepatocellular Carcinoma Patients: From Discovery to Clinical Development
Current Medicinal Chemistry Oncolytic Viruses: Programmable Tumour Hunters
Current Gene Therapy Urokinase-a Very Popular Cardiovascular Agent
Recent Patents on Cardiovascular Drug Discovery